BRIEF-Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva

by Reuters
Monday, 18 March 2019 11:05 GMT

March 18 (Reuters) - Novo Nordisk A/S:

* REG-NOVO NORDISK SETTLES U.S. PATENT LITIGATION CASE ON VICTOZA® (LIRAGLUTIDE) WITH TEVA

* SAYS TEVA IS LICENSED TO LAUNCH A GENERIC VERSION OF VICTOZAAS OF 22 DECEMBER 2023

* UNDER CERTAIN CIRCUMSTANCES TEVA COULD LAUNCH A GENERIC VERSION OF VICTOZA(®) EARLIER, BUT NOT BEFORE 22 MARCH 2023, UNLESS VICTOZA(®) PATENTS ARE NO LONGER IN FORCE OR THERE IS ANOTHER GENERIC VERSION OF VICTOZA(®) ON MARKET

* SAYS IF NOVO NORDISK IS GRANTED SIX MONTHS PAEDIATRIC EXTENSION FOR VICTOZA(®), ALL ABOVE-MENTIONED TIMELINES WILL BE EXTENDED BY SIX MONTHS

* SAYS - AGREEMENT IS SUBJECT TO REVIEW BY US FEDERAL TRADE COMMISSION AND US DEPARTMENT OF JUSTICE Source text for Eikon: Further company coverage: (Reporting by Jacob Gronholt-Pedersen)

Our Standards: The Thomson Reuters Trust Principles.